A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Placebo; Drug: MK-0941; Drug: Insulin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00824616

0941-018

MK-0941-018 (Other Identifier)

2009_516 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.

Enrollment: 68 patients

Sex: All

Ages: 21 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant has Type 2 Diabetes Mellitus

Exclusion criteria

• Participant has a history of Type 1 Diabetes Mellitus or ketoacidosis
• Participant is on a weight loss program and is not in the maintenance phase or is taking a weight loss medication
• Participant has had surgery within 30 days of starting the study or has planned major surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

68 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Participants receiving placebo tablets three times daily plus insulin injection once daily

Treatment:

Drug: Insulin

Drug: Placebo

MK-0941

Experimental group

Description:

Participants receiving MK-0941 tablets three times daily plus insulin injection once daily

Treatment:

Drug: Insulin

Drug: MK-0941